Biogen hit by ALS setback with PhIII failure for tofersen — but follows a familiar strategy highlighting the positive
Patients and analysts waiting to hear Sunday how Biogen’s SOD1-ALS drug tofersen fared in Phase III didn’t have to wait long for the top-line result they were all waiting for. The drug failed the primary endpoint on significantly improving the functional and neurologic decline of patients over 28 weeks as well as the extension period for continued observation.
In fact, there was very little difference in response.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 125,100+ biopharma pros reading Endpoints daily — and it's free.